Cyclic Peptide [R 4 W 4] in Bettering the Capacity of First-Line Antibiotics to Inhibit Mycobacterium tuberculosis Inside in vitro Human Granulomas
Tuberculosis (TB) is at the moment one of many main causes of world mortality. Medical non-compliance because of the size of the remedy and antibiotic unwanted effects has led to the emergence of multidrug-resistant (MDR) strains of Mycobacterium tuberculosis (M. tb) which might be tough to deal with.
A present therapeutic technique trying to avoid this concern goals to reinforce drug supply to scale back the period of the antibiotic routine or dosage of first-line antibiotics. One such agent which will assistance is cyclic peptide [R4W4], because it has been proven to have antibacterial properties (together with tetracycline) in opposition to methicillin-resistant Staphylococcus aureus (MRSA) up to now.
The target of this examine is to check cyclic peptide [R4W4] each alone and together with present first-line antibiotics (both isoniazid or pyrazinamide) to review the consequences of inhibition of M. tb inside in vitro human granulomas. Outcomes from our research point out that [R4W4] is efficacious in controlling M. tb an infection within the granulomas and has enhanced inhibitory results within the presence of first-line antibiotics.
antibodysource
PTCHD1 Peptide |
|||
| 42-686P | ProSci | 0.1 mg | 405.6 EUR |
|
Description: (IN) PTCHD1 Peptide |
|||
PTCHD1 Immunizing Peptide |
|||
| MBS427529-01mg | MyBiosource | 0.1mg | 225 EUR |
PTCHD3 Immunizing Peptide |
|||
| MBS427798-01mg | MyBiosource | 0.1mg | 225 EUR |
PTCHD2 Antibody |
|||
| 4915-002mg | ProSci | 0.02 mg | 206.18 EUR |
|
Description: PTCHD2 Antibody: PTCHD2, also known as DISP3, is the third of three known homologs of the D. melanogaster protein Dispatched. It is a multi-transmembrane protein containing two PTCH/DISP domains and is thought to be involved in the release of lipid-anchored secreted proteins. Like DISP1 and DISP2, DISP3 has been implicated in signaling pathways during embryogenesis, tissue regeneration, and carcinogenesis. It is highly expressed in Purkinje cells, hippocampal neurons, and retinal ganglion cells. Recently, it has been shown that PTCHD2 localizes within the endoplasmic reticulum and colocalizes with cholesterol, and given that its expression is regulated by thyroid hormone (T3), it has been suggested that DISP3 may be a link between thyroid hormone and cholesterol metabolism. |
|||
PTCHD2 Antibody |
|||
| 4915-01mg | ProSci | 0.1 mg | 523.7 EUR |
|
Description: PTCHD2 Antibody: PTCHD2, also known as DISP3, is the third of three known homologs of the D. melanogaster protein Dispatched. It is a multi-transmembrane protein containing two PTCH/DISP domains and is thought to be involved in the release of lipid-anchored secreted proteins. Like DISP1 and DISP2, DISP3 has been implicated in signaling pathways during embryogenesis, tissue regeneration, and carcinogenesis. It is highly expressed in Purkinje cells, hippocampal neurons, and retinal ganglion cells. Recently, it has been shown that PTCHD2 localizes within the endoplasmic reticulum and colocalizes with cholesterol, and given that its expression is regulated by thyroid hormone (T3), it has been suggested that DISP3 may be a link between thyroid hormone and cholesterol metabolism. |
|||
PTCHD2 Antibody |
|||
| 4925-002mg | ProSci | 0.02 mg | 206.18 EUR |
|
Description: PTCHD2 Antibody: PTCHD2, also known as DISP3, is the third of three known homologs of the D. melanogaster protein Dispatched. It is a multi-transmembrane protein containing two PTCH/DISP domains and is thought to be involved in the release of lipid-anchored secreted proteins. Like DISP1 and DISP2, DISP3 has been implicated in signaling pathways during embryogenesis, tissue regeneration, and carcinogenesis. It is highly expressed in Purkinje cells, hippocampal neurons, and retinal ganglion cells. Recently, it has been shown that PTCHD2 localizes within the endoplasmic reticulum and colocalizes with cholesterol, and given that its expression is regulated by thyroid hormone (T3), it has been suggested that DISP3 may be a link between thyroid hormone and cholesterol metabolism. |
|||
PTCHD2 Antibody |
|||
| 4925-01mg | ProSci | 0.1 mg | 523.7 EUR |
|
Description: PTCHD2 Antibody: PTCHD2, also known as DISP3, is the third of three known homologs of the D. melanogaster protein Dispatched. It is a multi-transmembrane protein containing two PTCH/DISP domains and is thought to be involved in the release of lipid-anchored secreted proteins. Like DISP1 and DISP2, DISP3 has been implicated in signaling pathways during embryogenesis, tissue regeneration, and carcinogenesis. It is highly expressed in Purkinje cells, hippocampal neurons, and retinal ganglion cells. Recently, it has been shown that PTCHD2 localizes within the endoplasmic reticulum and colocalizes with cholesterol, and given that its expression is regulated by thyroid hormone (T3), it has been suggested that DISP3 may be a link between thyroid hormone and cholesterol metabolism. |
|||
PTCHD2 Antibody |
|||
| 6637-002mg | ProSci | 0.02 mg | 206.18 EUR |
|
Description: PTCHD2 Antibody: PTCHD2, also known as DISP3, is the third of three known homologs of the D. melanogaster protein Dispatched. It is a multi-transmembrane protein containing two PTCH/DISP domains and is thought to be involved in the release of lipid-anchored secreted proteins. Like DISP1 and DISP2, DISP3 has been implicated in signaling pathways during embryogenesis, tissue regeneration, and carcinogenesis. It is highly expressed in Purkinje cells, hippocampal neurons, and retinal ganglion cells. Recently, it has been shown that PTCHD2 localizes within the endoplasmic reticulum and colocalizes with cholesterol, and given that its expression is regulated by thyroid hormone (T3), it has been suggested that DISP3 may be a link between thyroid hormone and cholesterol metabolism. |
|||
PTCHD2 Antibody |
|||
| 6637-01mg | ProSci | 0.1 mg | 523.7 EUR |
|
Description: PTCHD2 Antibody: PTCHD2, also known as DISP3, is the third of three known homologs of the D. melanogaster protein Dispatched. It is a multi-transmembrane protein containing two PTCH/DISP domains and is thought to be involved in the release of lipid-anchored secreted proteins. Like DISP1 and DISP2, DISP3 has been implicated in signaling pathways during embryogenesis, tissue regeneration, and carcinogenesis. It is highly expressed in Purkinje cells, hippocampal neurons, and retinal ganglion cells. Recently, it has been shown that PTCHD2 localizes within the endoplasmic reticulum and colocalizes with cholesterol, and given that its expression is regulated by thyroid hormone (T3), it has been suggested that DISP3 may be a link between thyroid hormone and cholesterol metabolism. |
|||
PTCHD2 Antibody |
|||
| 25404 | SAB | 100ul | 479 EUR |
PTCHD2 Antibody |
|||
| 25404-100ul | SAB | 100ul | 468 EUR |
PTCHD2 Antibody |
|||
| 24792 | SAB | 100ul | 479 EUR |
PTCHD2 Antibody |
|||
| 24792-100ul | SAB | 100ul | 468 EUR |
PTCHD2 Antibody |
|||
| 24797 | SAB | 100ul | 479 EUR |
PTCHD2 Antibody |
|||
| 24797-100ul | SAB | 100ul | 468 EUR |
PTCHD2 Antibody |
|||
| MBS151200-01mg | MyBiosource | 0.1mg | 445 EUR |
PTCHD2 Antibody |
|||
| MBS151200-5x01mg | MyBiosource | 5x0.1mg | 1965 EUR |
PTCHD2 Antibody |
|||
| MBS151575-01mg | MyBiosource | 0.1mg | 445 EUR |
PTCHD2 Antibody |
|||
| MBS151575-5x01mg | MyBiosource | 5x0.1mg | 1965 EUR |
PTCHD2 Antibody |
|||
| MBS151579-01mg | MyBiosource | 0.1mg | 445 EUR |
PTCHD2 Antibody |
|||
| MBS151579-5x01mg | MyBiosource | 5x0.1mg | 1965 EUR |
PTCHD2 Antibody |
|||
| MBS9410982-01mL | MyBiosource | 0.1mL | 495 EUR |
PTCHD2 Antibody |
|||
| MBS9410982-5x01mL | MyBiosource | 5x0.1mL | 2075 EUR |
PTCHD2 Antibody |
|||
| MBS9407915-01mL | MyBiosource | 0.1mL | 495 EUR |
PTCHD2 Antibody |
|||
| MBS9407915-5x01mL | MyBiosource | 5x0.1mL | 2075 EUR |
PTCHD2 Antibody |
|||
| MBS9408772-01mL | MyBiosource | 0.1mL | 495 EUR |
PTCHD2 Antibody |
|||
| MBS9408772-5x01mL | MyBiosource | 5x0.1mL | 2075 EUR |
PTCHD2 (untagged)-Human patched domain containing 2 (PTCHD2) |
|||
| SC316598 | Origene Technologies GmbH | 10 µg | Ask for price |
PTCHD2 (GFP-tagged) - Human patched domain containing 2 (PTCHD2) |
|||
| RG211355 | Origene Technologies GmbH | 10 µg | Ask for price |
Ptchd2 (untagged) - Mouse patched domain containing 2 (Ptchd2), (10ug) |
|||
| MC224316 | Origene Technologies GmbH | 10 µg | Ask for price |
Human PTCHD2 siRNA |
|||
| 20-abx930257 | Abbexa |
|
|
PTCHD2 siRNA (Human) |
|||
| MBS8237840-15nmol | MyBiosource | 15nmol | 405 EUR |
PTCHD2 siRNA (Human) |
|||
| MBS8237840-30nmol | MyBiosource | 30nmol | 565 EUR |
PTCHD2 siRNA (Human) |
|||
| MBS8237840-5x30nmol | MyBiosource | 5x30nmol | 2450 EUR |
PTCHD1 Antibody (Center) Blocking peptide |
|||
| MBS9218358-INQUIRE | MyBiosource | INQUIRE | Ask for price |
PTCHD3 Antibody (C-term) Blocking peptide |
|||
| MBS9218367-INQUIRE | MyBiosource | INQUIRE | Ask for price |
Ptchd2 (GFP-tagged) - Mouse patched domain containing 2 (Ptchd2), (10ug) |
|||
| MG223294 | Origene Technologies GmbH | 10 µg | Ask for price |
Ptchd2 (Myc-DDK-tagged) - Mouse patched domain containing 2 (Ptchd2) |
|||
| MR223294 | Origene Technologies GmbH | 10 µg | Ask for price |
PTCHD2 (Myc-DDK-tagged)-Human patched domain containing 2 (PTCHD2) |
|||
| RC211355 | Origene Technologies GmbH | 10 µg | Ask for price |
Polyclonal PTCHD2 Antibody |
|||
| AMR09590G | Leading Biology | 0.1 mg | 790.8 EUR |
|
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human PTCHD2 . This antibody is tested and proven to work in the following applications: |
|||
Polyclonal PTCHD2 Antibody |
|||
| AMR09591G | Leading Biology | 0.1 mg | 790.8 EUR |
|
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human PTCHD2 . This antibody is tested and proven to work in the following applications: |
|||
Polyclonal PTCHD2 Antibody |
|||
| AMR09592G | Leading Biology | 0.1 mg | 790.8 EUR |
|
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human PTCHD2 . This antibody is tested and proven to work in the following applications: |
|||
PTCHD2 Polyclonal Antibody |
|||
| MBS9234398-01mL | MyBiosource | 0.1mL | 415 EUR |
PTCHD2 Polyclonal Antibody |
|||
| MBS9234398-5x01mL | MyBiosource | 5x0.1mL | 1841 EUR |
Human PTCHD2 shRNA Plasmid |
|||
| 20-abx961520 | Abbexa |
|
|
Lenti ORF clone of Ptchd2 (mGFP-tagged) - Mouse patched domain containing 2 (Ptchd2) |
|||
| MR223294L4 | Origene Technologies GmbH | 10 µg | Ask for price |
Rabbit Polyclonal PTCHD2 Antibody |
|||
| TA319981 | Origene Technologies GmbH | 100 µg | Ask for price |
Rabbit Polyclonal PTCHD2 Antibody |
|||
| TA319982 | Origene Technologies GmbH | 100 µg | Ask for price |
Rabbit Polyclonal PTCHD2 Antibody |
|||
| TA319983 | Origene Technologies GmbH | 100 µg | Ask for price |
AAP94899-100UG - Ptchd3 Blocking peptide (N terminal region) |
|||
| AAP94899-100UG | Aviva Systems Biology | 100ug | 99 EUR |
PTCHD2 ORF Vector (Human) (pORF) |
|||
| ORF028512 | ABM | 1.0 ug DNA | Ask for price |
Ptchd2 ORF Vector (Mouse) (pORF) |
|||
| ORF055152 | ABM | 1.0 ug DNA | 1886.4 EUR |
Lenti ORF clone of Ptchd2 (Myc-DDK-tagged) - Mouse patched domain containing 2 (Ptchd2) |
|||
| MR223294L3 | Origene Technologies GmbH | 10 µg | Ask for price |
Human PTCHD2 knockout cell line |
|||
| ABC-KH12357 | AcceGen | 1 vial | Ask for price |
|
Description: Human PTCHD2 knockout cell line is HEK293/HeLa cell line, edited by CRISPR/Cas9 technology. |
|||
Human PTCHD2 knockdown cell line |
|||
| ABC-KD12357 | AcceGen | 1 vial | Ask for price |
|
Description: Human PTCHD2 knockdown cell line is engineered by our optimized transduction of the specific shRNA with lentivirus. Knockdown levels are determined via qRT-PCR. Gentaur offers generation of stable knockdown (RNAi) cell lines expressing shRNAs targeting genes of your interest. |
|||
Mast Cell-Degranulating Peptide (MCD Peptide) / Peptide 401 |
|||
| 004-04 | PHOENIX PEPTIDE | 100 μg | 140.4 EUR |
Polyclonal PTCHD2 Antibody (N-Terminus) |
|||
| AMR09593G | Leading Biology | 0.05mg | 580.8 EUR |
|
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human PTCHD2 (N-Terminus). This antibody is tested and proven to work in the following applications: |
|||
Lenti ORF particles, Ptchd2 (GFP-tagged) - Mouse patched domain containing 2 (Ptchd2), 200ul, >10^7 TU/mL |
|||
| MR223294L4V | Origene Technologies GmbH | 200 µl | Ask for price |
Lenti ORF particles, PTCHD2 (mGFP-tagged) - Human patched domain containing 2 (PTCHD2), 200ul, >10^7 TU/mL |
|||
| RC211355L2V | Origene Technologies GmbH | 200 µl | Ask for price |
Lenti ORF particles, PTCHD2 (mGFP-tagged) - Human patched domain containing 2 (PTCHD2), 200ul, >10^7 TU/mL |
|||
| RC211355L4V | Origene Technologies GmbH | 200 µl | Ask for price |
Lenti ORF particles, PTCHD2 (Myc-DDK tagged) - Human patched domain containing 2 (PTCHD2), 200ul, >10^7 TU/mL |
|||
| RC211355L1V | Origene Technologies GmbH | 200 µl | Ask for price |
Lenti ORF particles, PTCHD2 (Myc-DDK tagged) - Human patched domain containing 2 (PTCHD2), 200ul, >10^7 TU/mL |
|||
| RC211355L3V | Origene Technologies GmbH | 200 µl | Ask for price |
Lenti ORF particles, Ptchd2 (Myc-DDK-tagged) - Mouse patched domain containing 2 (Ptchd2), 200ul, >10^7 TU/mL |
|||
| MR223294L3V | Origene Technologies GmbH | 200 µl | Ask for price |
PTCHD2 3'UTR GFP Stable Cell Line |
|||
| TU069132 | ABM | 1.0 ml | 1672.8 EUR |
Ptchd2 3'UTR GFP Stable Cell Line |
|||
| TU167223 | ABM | 1.0 ml | Ask for price |
PTCHD2 sgRNA CRISPR Lentivector set (Human) |
|||
| K1748901 | ABM | 3 x 1.0 ug | 406.8 EUR |
Ptchd2 sgRNA CRISPR Lentivector set (Mouse) |
|||
| K3185201 | ABM | 3 x 1.0 ug | 406.8 EUR |
OAPB01435-100UG - PTCHD2 Antibody - C-terminal |
|||
| OAPB01435-100UG | Aviva Systems Biology | 100ug | 389 EUR |
OAPB01436-100UG - PTCHD2 Antibody - N-terminal |
|||
| OAPB01436-100UG | Aviva Systems Biology | 100ug | 389 EUR |
OAPB01521-100UG - PTCHD2 Antibody - N-terminal |
|||
| OAPB01521-100UG | Aviva Systems Biology | 100ug | 389 EUR |
Peptide T |
|||
| 057-01 | PHOENIX PEPTIDE | 5 mg | 140.4 EUR |
PTCHD2 Protein Vector (Human) (pPM-C-HA) |
|||
| PV114048 | ABM | 500 ng | Ask for price |
PTCHD2 Protein Vector (Mouse) (pPM-C-HA) |
|||
| PV220608 | ABM | 500 ng | 2766 EUR |
FGL Peptide |
|||
| 073-36 | PHOENIX PEPTIDE | 100 μg | 214.92 EUR |
APK peptide |
|||
| 076-81 | PHOENIX PEPTIDE | 200 μg | 199.8 EUR |
NEF peptide |
|||
| 076-83 | PHOENIX PEPTIDE | 500 μg | 140.4 EUR |
SHA peptide |
|||
| 076-84 | PHOENIX PEPTIDE | 500 μg | 177.12 EUR |
YSY peptide |
|||
| 076-86 | PHOENIX PEPTIDE | 100 μg | 230.04 EUR |
PTCHD2 Protein Vector (Human) (pPB-C-His) |
|||
| PV114046 | ABM | 500 ng | Ask for price |
PTCHD2 Protein Vector (Human) (pPB-N-His) |
|||
| PV114047 | ABM | 500 ng | Ask for price |
PTCHD2 Protein Vector (Human) (pPM-C-His) |
|||
| PV114049 | ABM | 500 ng | Ask for price |
PTCHD2 Protein Vector (Mouse) (pPB-C-His) |
|||
| PV220606 | ABM | 500 ng | 2766 EUR |
PTCHD2 Protein Vector (Mouse) (pPB-N-His) |
|||
| PV220607 | ABM | 500 ng | 2766 EUR |
PTCHD2 Protein Vector (Mouse) (pPM-C-His) |
|||
| PV220609 | ABM | 500 ng | 2766 EUR |
PTCHD2 3'UTR Luciferase Stable Cell Line |
|||
| TU019132 | ABM | 1.0 ml | 1672.8 EUR |
Ptchd2 3'UTR Luciferase Stable Cell Line |
|||
| TU117223 | ABM | 1.0 ml | Ask for price |
Peptide E / 3200-Dalton Adrenal Enkephalin-Containing Peptide (Bovine) |
|||
| 024-57 | PHOENIX PEPTIDE | 200 μg | 86.4 EUR |
PSTAIR Peptide |
|||
| 070-61 | PHOENIX PEPTIDE | 500 μg | 129.6 EUR |
PGMtide Peptide |
|||
| 040-69 | PHOENIX PEPTIDE | 100 μg | 316.44 EUR |
Adjuvant Peptide |
|||
| 070-05 | PHOENIX PEPTIDE | 500 μg | 36.72 EUR |
Peptide-epsilon |
|||
| 058-22 | PHOENIX PEPTIDE | 500 μg | 114.48 EUR |
Delicious Peptide |
|||
| 070-21 | PHOENIX PEPTIDE | 5 mg | 160.92 EUR |
proSex peptide (20-55) |
|||
| 040-30 | PHOENIX PEPTIDE | 100 μg | 355.32 EUR |
proSex peptide (28-55) |
|||
| 040-31 | PHOENIX PEPTIDE | 100 μg | 282.96 EUR |
proSex peptide (40-55) |
|||
| 040-32 | PHOENIX PEPTIDE | 100 μg | 214.92 EUR |
Bombinin-Like Peptide 1 amide / prepro-Bombinin-Like Peptide (44-70) amide / prepro-Bombinin-Like Peptide (107-133) amide |
|||
| 007-60 | PHOENIX PEPTIDE | 100 μg | 214.92 EUR |
Peptide F-9 |
|||
| 038-06 | PHOENIX PEPTIDE | 200 μg | 58.32 EUR |
Sturgeon Peptide (137-158) |
|||
| 021-94 | PHOENIX PEPTIDE | 100 μg | 177.12 EUR |
Peptide Lv (Rat) |
|||
| 008-73 | PHOENIX PEPTIDE | 100 μg | 469.8 EUR |
NGR Peptide 1 |
|||
| 025-74 | PHOENIX PEPTIDE | 200 μg | 184.68 EUR |
Anorexigenic Peptide |
|||
| 070-10 | PHOENIX PEPTIDE | 5 mg | 86.4 EUR |
GnRH Associated Peptide (GAP) (1-13) / GnRH Precursor Peptide (14-26) (Human) |
|||
| 029-03 | PHOENIX PEPTIDE | 500 μg | 114.48 EUR |
GnRH Associated Peptide (GAP) (1-24) / GnRH Precursor Peptide (14-37) (Human) |
|||
| 029-04 | PHOENIX PEPTIDE | 100 μg | 114.48 EUR |
GnRH Associated Peptide (GAP) (1-53) / GnRH Precursor Peptide (14-66) (Human) |
|||
| 029-05 | PHOENIX PEPTIDE | 20 μg | 267.84 EUR |
GnRH Associated Peptide (GAP) (25-53) / GnRH Precursor Peptide (38-66) (Human) |
|||
| 029-06 | PHOENIX PEPTIDE | 100 μg | 114.48 EUR |
Bid BH3 peptide |
|||
| 025-87 | PHOENIX PEPTIDE | 1 mg | 170.64 EUR |
AF-16 Peptide |
|||
| 033-44 | PHOENIX PEPTIDE | 200 μg | 214.92 EUR |
PTCHD2 sgRNA CRISPR Lentivector (Human) (Target 1) |
|||
| K1748902 | ABM | 1.0 ug DNA | 184.8 EUR |
PTCHD2 sgRNA CRISPR Lentivector (Human) (Target 2) |
|||
| K1748903 | ABM | 1.0 ug DNA | 184.8 EUR |
PTCHD2 sgRNA CRISPR Lentivector (Human) (Target 3) |
|||
| K1748904 | ABM | 1.0 ug DNA | 184.8 EUR |
Antimicrobial resistance of ocular microbes and the position of antimicrobial peptides
Isolation of antimicrobial-resistant microbes from ocular infections could also be turning into extra frequent. Infections brought on by these microbes will be tough to deal with and result in poor outcomes. Nevertheless, new therapies are being developed which can assist enhance medical outcomes. This assessment examines current experiences on the isolation of antibiotic-resistant microbes from ocular infections. As well as, an summary of the event of some new antibiotic therapies is given.
The current literature concerning antibiotic use and resistance, isolation of antibiotic-resistant microbes from ocular infections and the event of potential new antibiotics that can be utilized to deal with these infections was reviewed. Ocular microbial infections are a world public well being concern as they can lead to imaginative and prescient loss which compromises high quality of life. Roughly 70 per cent of ocular infections are brought on by micro organism together with Chlamydia trachomatis, Staphylococcus aureus, and Pseudomonas aeruginosa and fungi equivalent to Candida albicans, Aspergillus spp. and Fusarium spp.
Resistance to first-line antibiotics equivalent to fluoroquinolones and azoles has elevated, with resistance of S. aureus isolates from the USA to fluoroquinolones reaching 32 per cent of isolates and 35 per cent being methicillin-resistant (MRSA). Decrease ranges of MRSA (seven per cent) have been remoted by an Australian examine. Antimicrobial peptides, that are broad-spectrum options to antibiotics, have been examined as doable new medicine. A number of have proven promise in animal fashions of keratitis, particularly treating P. aeruginosa, S. aureus or C. albicans infections.
Stories of accelerating resistance of ocular isolates to mainstay antibiotics are a priority, and there may be proof that for ocular floor illness this resistance interprets into worse medical outcomes. New antibiotics are being developed, however not by giant pharmaceutical firms and largely in college analysis laboratories and smaller biotech firms. Antimicrobial peptides present promise in treating keratitis.
Research on Adenovirus An infection in vitro with Nanoself-Assembling Peptide as Scaffolds for 3D Tradition
Objective: To assemble a three-dimensional (3D) tradition mannequin of adenovirus in vitro utilizing the nanoself-assembling peptide RADA16-I as a 3D cell tradition scaffold mixed with virology experimental know-how to supply a novel analysis technique for virus isolation and tradition, pathogenesis analysis, antiviral drug screening and vaccine preparation.
Strategies: The nanoself-assembling peptide RADA16-I used to be used as a 3D scaffold materials for 293T cell tradition, and adenovirus was cultured within the cells. The expansion, morphological traits and pathological results of 3D-cultured 293T cells after adenovirus an infection have been noticed with an inverted microscope and MTS. The proliferation of adenovirus in 293T cells was noticed by TEM and detected by qPCR. The degrees of TNF-α and IL-Eight secreted by adenovirus-infected 293T cells within the RADA16-I 3D tradition system have been detected by ELISA.
Outcomes: The 293T cells grew nicely within the RADA16-I 3D tradition system for a chronic time frame. The adenovirus an infection endured for a very long time with a number of proliferation peaks, which intently resembled these of in vivo infections. The adenovirus virions amplified within the 3D system remained infectious. There have been a number of secretion peaks of TNF-α and IL-Eight secretion ranges in adenovirus-infected 293T cells cultured in 3D tradition methods.
Conclusion: The nanoself-assembling peptide RADA16-I can be utilized as a 3D scaffold for adenovirus isolation, tradition and analysis. The 3D tradition system exhibits extra real looking in vivo results than two-dimensional (2D) tradition.
Bcl6 Blocking Peptide |
|||
| DF2903-BP | Affbiotech | 1mg | 234 EUR |
BCL6 Blocking Peptide |
|||
| 20-abx162090 | Abbexa |
|
|
Bcl6 Blocking Peptide |
|||
| MBS5400586-025mg | MyBiosource | 0.25mg | 280 EUR |
Bcl6 Blocking Peptide |
|||
| MBS5400586-5x025mg | MyBiosource | 5x0.25mg | 1110 EUR |
Bcl6 Blocking Peptide |
|||
| MBS5400587-025mg | MyBiosource | 0.25mg | 280 EUR |
Bcl6 Blocking Peptide |
|||
| MBS5400587-5x025mg | MyBiosource | 5x0.25mg | 1110 EUR |
BCL6 Blocking Peptide |
|||
| MBS829496-1mg | MyBiosource | 1mg | 190 EUR |
BCL6 Blocking Peptide |
|||
| MBS829496-5mg | MyBiosource | 5mg | 345 EUR |
BCL6 Blocking Peptide |
|||
| MBS829496-5x5mg | MyBiosource | 5x5mg | 1465 EUR |
BCL6 Blocking Peptide |
|||
| MBS8224220-1mg | MyBiosource | 1mg | 190 EUR |
BCL6 Blocking Peptide |
|||
| MBS8224220-5mg | MyBiosource | 5mg | 345 EUR |
BCL6 Blocking Peptide |
|||
| MBS8224220-5x5mg | MyBiosource | 5x5mg | 1465 EUR |
BCL6 Blocking Peptide |
|||
| MBS8243946-1mg | MyBiosource | 1mg | 190 EUR |
BCL6 Blocking Peptide |
|||
| MBS8243946-5mg | MyBiosource | 5mg | 345 EUR |
BCL6 Blocking Peptide |
|||
| MBS8243946-5x5mg | MyBiosource | 5x5mg | 1465 EUR |
Bcl6 Blocking Peptide |
|||
| MBS9623094-1mg | MyBiosource | 1mg | 380 EUR |
Bcl6 Blocking Peptide |
|||
| MBS9623094-5x1mg | MyBiosource | 5x1mg | 1650 EUR |
Bcl6 Blocking Peptide |
|||
| MBS9617774-1mg | MyBiosource | 1mg | 380 EUR |
Bcl6 Blocking Peptide |
|||
| MBS9617774-5x1mg | MyBiosource | 5x1mg | 1650 EUR |
Mast Cell-Degranulating Peptide (MCD Peptide) / Peptide 401 |
|||
| 004-04 | PHOENIX PEPTIDE | 100 μg | 140.4 EUR |
BCL6 (pS333) Blocking Peptide |
|||
| 20-abx161559 | Abbexa |
|
|
BCL6 (pS333) Blocking Peptide |
|||
| MBS8208184-1mg | MyBiosource | 1mg | 230 EUR |
BCL6 (pS333) Blocking Peptide |
|||
| MBS8208184-5mg | MyBiosource | 5mg | 475 EUR |
BCL6 (pS333) Blocking Peptide |
|||
| MBS8208184-5x5mg | MyBiosource | 5x5mg | 2060 EUR |
BCL6 Blocking Peptide (Center) |
|||
| MBS9230337-INQUIRE | MyBiosource | INQUIRE | Ask for price |
BCL6 Peptide - C-terminal region |
|||
| MBS3225644-01mg | MyBiosource | 0.1mg | 180 EUR |
BCL6 Peptide - C-terminal region |
|||
| MBS3225644-5x01mg | MyBiosource | 5x0.1mg | 730 EUR |
Peptide T |
|||
| 057-01 | PHOENIX PEPTIDE | 5 mg | 140.4 EUR |
FGL Peptide |
|||
| 073-36 | PHOENIX PEPTIDE | 100 μg | 214.92 EUR |
APK peptide |
|||
| 076-81 | PHOENIX PEPTIDE | 200 μg | 199.8 EUR |
NEF peptide |
|||
| 076-83 | PHOENIX PEPTIDE | 500 μg | 140.4 EUR |
SHA peptide |
|||
| 076-84 | PHOENIX PEPTIDE | 500 μg | 177.12 EUR |
YSY peptide |
|||
| 076-86 | PHOENIX PEPTIDE | 100 μg | 230.04 EUR |
Peptide E / 3200-Dalton Adrenal Enkephalin-Containing Peptide (Bovine) |
|||
| 024-57 | PHOENIX PEPTIDE | 200 μg | 86.4 EUR |
PSTAIR Peptide |
|||
| 070-61 | PHOENIX PEPTIDE | 500 μg | 129.6 EUR |
PGMtide Peptide |
|||
| 040-69 | PHOENIX PEPTIDE | 100 μg | 316.44 EUR |
Adjuvant Peptide |
|||
| 070-05 | PHOENIX PEPTIDE | 500 μg | 36.72 EUR |
Peptide-epsilon |
|||
| 058-22 | PHOENIX PEPTIDE | 500 μg | 114.48 EUR |
Delicious Peptide |
|||
| 070-21 | PHOENIX PEPTIDE | 5 mg | 160.92 EUR |
proSex peptide (20-55) |
|||
| 040-30 | PHOENIX PEPTIDE | 100 μg | 355.32 EUR |
proSex peptide (28-55) |
|||
| 040-31 | PHOENIX PEPTIDE | 100 μg | 282.96 EUR |
proSex peptide (40-55) |
|||
| 040-32 | PHOENIX PEPTIDE | 100 μg | 214.92 EUR |
Bombinin-Like Peptide 1 amide / prepro-Bombinin-Like Peptide (44-70) amide / prepro-Bombinin-Like Peptide (107-133) amide |
|||
| 007-60 | PHOENIX PEPTIDE | 100 μg | 214.92 EUR |
Peptide F-9 |
|||
| 038-06 | PHOENIX PEPTIDE | 200 μg | 58.32 EUR |
Sturgeon Peptide (137-158) |
|||
| 021-94 | PHOENIX PEPTIDE | 100 μg | 177.12 EUR |
Peptide Lv (Rat) |
|||
| 008-73 | PHOENIX PEPTIDE | 100 μg | 469.8 EUR |
NGR Peptide 1 |
|||
| 025-74 | PHOENIX PEPTIDE | 200 μg | 184.68 EUR |
Anorexigenic Peptide |
|||
| 070-10 | PHOENIX PEPTIDE | 5 mg | 86.4 EUR |
GnRH Associated Peptide (GAP) (1-13) / GnRH Precursor Peptide (14-26) (Human) |
|||
| 029-03 | PHOENIX PEPTIDE | 500 μg | 114.48 EUR |
GnRH Associated Peptide (GAP) (1-24) / GnRH Precursor Peptide (14-37) (Human) |
|||
| 029-04 | PHOENIX PEPTIDE | 100 μg | 114.48 EUR |
GnRH Associated Peptide (GAP) (1-53) / GnRH Precursor Peptide (14-66) (Human) |
|||
| 029-05 | PHOENIX PEPTIDE | 20 μg | 267.84 EUR |
GnRH Associated Peptide (GAP) (25-53) / GnRH Precursor Peptide (38-66) (Human) |
|||
| 029-06 | PHOENIX PEPTIDE | 100 μg | 114.48 EUR |
Bid BH3 peptide |
|||
| 025-87 | PHOENIX PEPTIDE | 1 mg | 170.64 EUR |
AF-16 Peptide |
|||
| 033-44 | PHOENIX PEPTIDE | 200 μg | 214.92 EUR |
Peptide Lv (Human) |
|||
| 008-71 | PHOENIX PEPTIDE | 100 μg | 405 EUR |
Peptide Lv (Mouse) |
|||
| 008-72 | PHOENIX PEPTIDE | 100 μg | 469.8 EUR |
GnRH Associated Peptide (GAP) (1-13) / Gn-RH Precursor Peptide (14-26) (Rat) |
|||
| 029-08 | PHOENIX PEPTIDE | 200 μg | 64.8 EUR |
ExE peptide M3mP6 |
|||
| 064-33 | PHOENIX PEPTIDE | 200 μg | 244.08 EUR |
Peptide B (Bovine) |
|||
| 024-56 | PHOENIX PEPTIDE | 200 μg | 81 EUR |
Peptide F (Bovine) |
|||
| 024-58 | PHOENIX PEPTIDE | 200 μg | 114.48 EUR |
PLP Peptide (103-116) (Bovine) |
|||
| 070-14 | PHOENIX PEPTIDE | 5 mg | 140.4 EUR |
FMRF-Like Peptide |
|||
| 047-32 | PHOENIX PEPTIDE | 1 mg | 27 EUR |
Joining Peptide (Rat) |
|||
| 047-91 | PHOENIX PEPTIDE | 200 μg | 160.92 EUR |
Growth Hormone-Releasing Peptide-Related Peptide-1 (fGRP-RP-1) (Frog) |
|||
| 048-80 | PHOENIX PEPTIDE | 500 μg | 177.12 EUR |
Growth Hormone-Releasing Peptide-Related Peptide-2 (fGRP-RP-2) (Frog) |
|||
| 048-81 | PHOENIX PEPTIDE | 200 μg | 214.92 EUR |
Growth Hormone-Releasing Peptide-Related Peptide-3 (fGRP-RP-3) (Frog) |
|||
| 048-82 | PHOENIX PEPTIDE | 200 μg | 214.92 EUR |
Peptide T (4-8) |
|||
| 057-04 | PHOENIX PEPTIDE | 500 μg | 64.8 EUR |
Peptide T (5-8) |
|||
| 057-05 | PHOENIX PEPTIDE | 500 μg | 64.8 EUR |
Vasonatrin Peptide (VNP) |
|||
| 005-47 | PHOENIX PEPTIDE | 200 μg | 214.92 EUR |
Opioid Peptide Library |
|||
| L-002 | PHOENIX PEPTIDE | 58 peptides | 2691.36 EUR |
Peptide Histidine Isoleucine 27 (PHI-27) / Porcine Intestinal Peptide (Porcine) |
|||
| 064-01 | PHOENIX PEPTIDE | 200 μg | 108 EUR |
PGMtide Control Peptide |
|||
| 040-70 | PHOENIX PEPTIDE | 100 μg | 316.44 EUR |
Growth Blocking Peptide |
|||
| 046-92 | PHOENIX PEPTIDE | 100 μg | 255.96 EUR |
Neuron Specific Peptide |
|||
| 047-55 | PHOENIX PEPTIDE | 200 μg | 140.4 EUR |
Heparin Binding Peptide |
|||
| 025-47 | PHOENIX PEPTIDE | 500 μg | 102.6 EUR |
Gastrin Related Peptide |
|||
| 027-09 | PHOENIX PEPTIDE | 5 mg | 73.44 EUR |
Obesity Peptide Library |
|||
| L-003 | PHOENIX PEPTIDE | 160 peptides | 7267.32 EUR |
[D-Ala1]-Peptide T |
|||
| 057-02 | PHOENIX PEPTIDE | 5 mg | 282.96 EUR |
Peptide YY (PYY) (Human) |
|||
| 059-01 | PHOENIX PEPTIDE | 200 μg | 119.88 EUR |
Eledoisin Related Peptide |
|||
| 046-04 | PHOENIX PEPTIDE | 5 mg | 58.32 EUR |
proSex peptide (28-55) - EIA Kit |
|||
| EK-040-31 | PHOENIX PEPTIDE | 96 wells | 603.72 EUR |
Peptide F 1 (Lobster) |
|||
| 047-62 | PHOENIX PEPTIDE | 500 μg | 73.44 EUR |
Morphine Tolerance Peptide |
|||
| 050-13 | PHOENIX PEPTIDE | 1 mg | 102.6 EUR |
Phosphate Acceptor Peptide |
|||
| 058-24 | PHOENIX PEPTIDE | 500 μg | 73.44 EUR |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) |
|||
| 064-07 | PHOENIX PEPTIDE | 200 μg | 114.48 EUR |
Peptide I / pro-Histine-Rich Basic Peptide (HRBP) (1-26) (Aplysia brasiliana) |
|||
| 047-39 | PHOENIX PEPTIDE | 200 μg | 444.96 EUR |
Peptide II / pro-Histine-Rich Basic Peptide (HRBP) (29-40) (Aplysia brasiliana) |
|||
| 047-40 | PHOENIX PEPTIDE | 500 μg | 214.92 EUR |
Peptide I / pro-Histine-Rich Basic Peptide (HRBP) (1-26) (Aplysia californica) |
|||
| 047-42 | PHOENIX PEPTIDE | 200 μg | 444.96 EUR |
Peptide II / pro-Histine-Rich Basic Peptide (HRBP) (29-40) (Aplysia californica) |
|||
| 047-43 | PHOENIX PEPTIDE | 500 μg | 214.92 EUR |
FGL Peptide - FAM Labeled |
|||
| FG-073-36A | PHOENIX PEPTIDE | 1 nmol | 405 EUR |